The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo

European Journal of Cancer

Volumn 49, Issue 15, 2013, Pages 3366-3375

  Heffeter, Petra ^a,b,c   Atil, Bihter ^a,b   Kryeziu, Kushtrim ^a,b   Groza, Diana ^a,b   Koellensperger, Gunda ^d   Körner, Wilfried ^e   Jungwirth, Ute ^a,b   Mohr, Thomas ^a,b   Keppler, Bernhard K ^d,e   Berger, Walter ^a,b,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Research Platform Translational Cancer Therapy Research Vienna   (Austria)

^d UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^e UNIVERSITY OF VIENNA   (Austria)

Author keywords

Drug accumulation P38; Ruthenium; Sorafenib; STAT3 Cell cycle arrest; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; KP 1339; MITOGEN ACTIVATED PROTEIN KINASE P38; RUTHENIUM DERIVATIVE; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG ACCUMULATION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIFESPAN; LIVER CELL CARCINOMA; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CELL CYCLE ARREST; DRUG ACCUMULATION; P38; RUTHENIUM; SORAFENIB; STAT3; SYNERGISM;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DRUG SYNERGISM; FEMALE; HETEROGRAFTS; HUMANS; MICE; MICE, SCID; NIACINAMIDE; ORGANOMETALLIC COMPOUNDS; PHENYLUREA COMPOUNDS; RUTHENIUM; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884910068     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.018     Document Type: Article

References (32)

1. R.E. Miller, and J.M. Larkin Combination systemic therapy for advanced renal cell carcinoma Oncologist 14 12 2009 1218 1224
2. Y.C. Shen, C. Hsu, and A.L. Cheng Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives J Gastroenterol 45 8 2010 794 807
3. P. Heffeter, U. Jungwirth, and M. Jakupec Resistance against novel anticancer metal compounds: differences and similarities Drug Resist Updat 11 1-2 2008 1 16
4. C.G. Hartinger, S. Zorbas-Seifried, and M.A. Jakupec From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A) J Inorg Biochem 100 5-6 2006 891 904
5. N.R. Dickson, S.F. Jones, and H.A. Burris III A phase I dose-escalation study of NKP-1339 in patients with advanced solid tumors refractory to treatment J Clin Oncol 29 suppl., abstr. 2607 2011
6. R. Iyer, G. Fetterly, A. Lugade, and Y. Thanavala Sorafenib: a clinical and pharmacologic review Expert Opin Pharmacother 11 11 2010 1943 1955
7. C. Yu, L.M. Bruzek, and X.W. Meng The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006 Oncogene 24 46 2005 6861 6869
8. J.F. Chiou, C.J. Tai, and Y.H. Wang Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism Cancer Biol Ther 8 20 2009 1904 1913
9. S.S. Singhal, A. Sehrawat, and M. Sahu Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer Int J Cancer 126 6 2010 1327 1338
10. S. Hu, Z. Chen, and R. Franke Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters Clin Cancer Res 15 19 2009 6062 6069
11. P. Heffeter, K. Bock, and B. Atil Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 J Biol Inorg Chem 15 5 2010 737 748
12. P. Heffeter, M.A. Jakupec, and W. Korner Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24) Biochem Pharmacol 73 12 2007 1873 1886
13. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
14. J.M. Wu, H. Sheng, and R. Saxena NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy Cancer Lett 278 2 2009 145 155
15. S. Kapitza, M.A. Jakupec, M. Uhl, B.K. Keppler, and B. Marian The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells Cancer Lett 226 2 2005 115 121
16. J.A. McCubrey, L.S. Steelman, and W.H. Chappell Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance Biochim Biophys Acta 1773 8 2007 1263 1284
17. E.D. Owuor, and A.N. Kong Antioxidants and oxidants regulated signal transduction pathways Biochem Pharmacol 64 5-6 2002 765 770
18. A. Mikhailov, M. Shinohara, and C.L. Rieder The p38-mediated stress-activated checkpoint. A rapid response system for delaying progression through antephase and entry into mitosis Cell Cycle 4 1 2005 57 62
19. T.M. Thornton, and M. Rincon Non-classical p38 map kinase functions: cell cycle checkpoints and survival Int J Biol Sci 5 1 2009 44 51
20. U. Jungwirth, C.R. Kowol, and C. Hartinger Anticancer activity of metal complexes: involvement of redox processes Antioxid Redox Signal 15 4 2011 1085 1127
21. S. Kapitza, M. Pongratz, and M.A. Jakupec Heterocyclic complexes of ruthenium(III) induce apoptosis in colorectal carcinoma cells J Cancer Res Clin Oncol 2004
22. A. Cuadrado, and A.R. Nebreda Mechanisms and functions of p38 MAPK signalling Biochem J 429 3 2010 403 417
23. M.S. Fenton, K.M. Marion, and A.K. Salem Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer Thyroid 20 9 2010 965 974
24. S. Shukla, R.W. Robey, S.E. Bates, and S.V. Ambudkar Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2 Drug Metab Dispos 37 2 2009 359 365
25. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat Rev Drug Discov 5 3 2006 219 234
26. P. Heffeter, M. Pongratz, and E. Steiner Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 indazolium trans-tetrachlorobis(1H-indazole)ruthenate (III) (FFC14A) J Pharmacol Exp Ther 312 1 2005 281 289
27. X. Gu, and J.E. Manautou Regulation of hepatic ABCC transporters by xenobiotics and in disease states Drug Metab Rev 42 3 2010 482 538
28. M. Matsuo ATP-binding cassette proteins involved in glucose and lipid homeostasis Biosci Biotechnol Biochem 74 5 2010 899 907
29. R. Januchowski, P. Zawierucha, M. Andrzejewska, M. Rucinski, and M. Zabel Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines Biomed Pharmacother 67 3 2013 240 245
30. S. Yadav, E. Zajac, S.S. Singhal, and S. Awasthi Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters Cancer Metastasis Rev 26 1 2007 59 69
31. R. Vatsyayan, P.C. Lelsani, S. Awasthi, and S.S. Singhal RLIP76: a versatile transporter and an emerging target for cancer therapy Biochem Pharmacol 79 12 2010 1699 1705
32. Y.C. Awasthi, P. Chaudhary, and R. Vatsyayan Physiological and pharmacological significance of glutathione-conjugate transport J Toxicol Environ Health B Crit Rev 12 7 2009 540 551